2025
A road map for uniform, comprehensive long-term follow-up after curative therapy for sickle cell disease
Shenoy S, Kanter J, Kassim A, Fitzhugh C, Stenger E, Bhatia M, Pecker L, Krishnamurti L, King A. A road map for uniform, comprehensive long-term follow-up after curative therapy for sickle cell disease. Blood Advances 2025, 9: 3090-3103. PMID: 39993235, DOI: 10.1182/bloodadvances.2024013953.Peer-Reviewed Original ResearchHistopathologic Progression of Autoimmune Atrophic Gastritis: A Retrospective Review of 180 Specimens From 32 Patients.
Wang X, Jiao J, Huh W, Zhang X. Histopathologic Progression of Autoimmune Atrophic Gastritis: A Retrospective Review of 180 Specimens From 32 Patients. Archives Of Pathology & Laboratory Medicine 2025 PMID: 40509896, DOI: 10.5858/arpa.2025-0030-oa.Peer-Reviewed Original ResearchAutoimmune atrophic gastritisFollow-up biopsiesNeuroendocrine tumorsFollow-upEndoscopic excisionEnterochromaffin-like cell hyperplasiaDevelopment of neuroendocrine tumorsLong-term follow-upKi-67 indexMinimal to mild inflammationImmune-mediated inflammationPathological progressionAverage follow-upEndoscopic surveillance intervalRetrospective reviewSurveillance intervalsKi-67Cell hyperplasiaGastric adenocarcinomaNo significant changesHistological featuresAntibody statusAtrophic gastritisClinical dataIntestinal metaplasiaLong-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus-Initiated Oropharynx Cancer.
Burtness B, Flamand Y, Quon H, Weinstein G, Mehra R, Garcia J, Kim S, O'Malley B, Ozer E, Ikpeazu C, Koch W, Gross N, Bell R, Patel M, Lango M, Morris L, Smith R, Karakla D, Richmon J, Holsinger F, Ferris R. Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus-Initiated Oropharynx Cancer. Journal Of Clinical Oncology 2025, jco2402550. PMID: 40493877, DOI: 10.1200/jco-24-02550.Peer-Reviewed Original ResearchExtranodal extensionOverall survivalOropharynx cancerTransoral surgeryRisk of late recurrenceLong-term follow-upFavorable pathologic characteristicsPhase II trialECOG-ACRINWeekly cisplatinN1 diseaseNeck dissectionProgression-freeLate recurrenceNeck nodesArm AAdjuvant treatmentSmoking historyPostoperative managementPathological characteristicsPrimary sitePFSPatientsSurgeryCancerLong-Term Results of External Beam Radiation Therapy with or Without Concurrent Chemotherapy in Differentiated Thyroid Cancer
Choi J, Sherman E, Dee E, Treechairusame T, Zakeri K, Kang J, Yu Y, Chen L, Shamseddine A, McBride S, Riaz N, Ho A, Tuttle R, Fagin J, Sabra M, Cracchiolo J, Shaha A, Wong R, Ghossein R, Katabi N, Lee N. Long-Term Results of External Beam Radiation Therapy with or Without Concurrent Chemotherapy in Differentiated Thyroid Cancer. Thyroid 2025, 35: 633-641. PMID: 40504742, DOI: 10.1089/thy.2025.0052.Peer-Reviewed Original ResearchConceptsTyrosine kinase inhibitorsExternal beam radiation therapyBeam radiation therapyConcurrent chemotherapyRadiation therapyTracheoesophageal fistulaLocoregional controlPercutaneous endoscopic gastrostomyOverall survivalResults of external beam radiation therapyPatients treated with concurrent chemotherapyFollow-upTKI initiationTreated with concurrent chemotherapyTyrosine kinase inhibitor therapyRare group of patientsLong-term follow-upGross residual diseaseTreated with RTRadioactive iodine therapySingle-institution experienceDifferentiated thyroid cancerMedian follow-upKaplan-Meier methodDay of RTCarfilzomib or bortezomib with lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Long-term follow-up of the ECOG-ACRIN ENDURANCE phase 3 trial.
Kumar S, Faber E, Cohen A, Callander N, Singh A, Parker T, Menter A, Yang X, Parsons B, Kumar P, Kapoor P, Aaron R, Zonder J, Anderson K, Lonial S, Richardson P, Orlowski R, Wagner L, Rajkumar S, Jacobus S. Carfilzomib or bortezomib with lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Long-term follow-up of the ECOG-ACRIN ENDURANCE phase 3 trial. Journal Of Clinical Oncology 2025, 43: 7540-7540. DOI: 10.1200/jco.2025.43.16_suppl.7540.Peer-Reviewed Original ResearchNewly diagnosed myelomaProgression free survivalPhase 3 trialTreatment of newly diagnosed myelomaMedian progression free survivalRandomized phase 3 trialNewly diagnosed multiple myelomaLong-term follow-upProteasome inhibitorsBortezomib (VPlasma cell leukemiaLong-term resultsIntent to transplantR-maintenanceOS probabilityMedian followFree survivalInduction regimenCell leukemiaMedian ageSurvival outcomesMultiple myelomaInitial treatmentBaseline characteristicsFollow-upSurgical treatment of a unilateral congenital cataract with persistent hyperplastic primary vitreous using double optic capture with a 20 year follow-up and review of the literature
DeBroff B. Surgical treatment of a unilateral congenital cataract with persistent hyperplastic primary vitreous using double optic capture with a 20 year follow-up and review of the literature. American Journal Of Ophthalmology Case Reports 2025, 38: 102341. DOI: 10.1016/j.ajoc.2025.102341.Peer-Reviewed Original ResearchPersistent hyperplastic primary vitreousHyperplastic primary vitreousIntraocular lens exchangeUnilateral congenital cataractPrimary vitreousLens exchangeYear follow-upFollow-upOptic captureIntraocular lensUnilateral cataractCongenital cataractPosterior chamber intraocular lens implantationLong-term follow-upIntraocular lens implantationPrimary posterior capsulorhexisAnterior capsulorhexisAnterior vitrectomyCapsulotomy openingIOL exchangeLens implantationPosterior capsulorhexisCataract surgeryVisual acuityLeft eyesStudy EV-103 cohort H: Neoadjuvant treatment with enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) with muscle invasive bladder cancer (MIBC)—3-year efficacy results.
Mar N, Petrylak D, Hoimes C, Rosenberg J, Flaig T, Gourdin T, Barata P, Henry E, Bilen M, George S, Rao S, Assikis V, Burgess E, Lewis B, Srinivas S, Gorla S, Meng C, Zhu Y, O'Donnell P. Study EV-103 cohort H: Neoadjuvant treatment with enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) with muscle invasive bladder cancer (MIBC)—3-year efficacy results. Journal Of Clinical Oncology 2025, 43: 4583-4583. DOI: 10.1200/jco.2025.43.16_suppl.4583.Peer-Reviewed Original ResearchMedian event-free survivalPathological complete responseEvent-free survivalInvestigator assessmentEnfortumab vedotinEfficacy resultsOS ratesNeoadjuvant treatmentSafety profileFollow-upPathologic complete response ratePelvic lymph node dissectionEvent-free survival rateAntitumor activityLong-term follow-upCentral pathology reviewEstimated OS ratesNeoadjuvant treatment optionsLymph node dissectionMedian follow-upPhase 3 trialCT2-T4aN0M0Median OSConsistent with prior reportsComplete responseARCHES: 5-year follow-up overall survival (OS) analysis of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC).
Armstrong A, Petrylak D, Shore N, Szmulewitz R, Holzbeierlein J, Villers A, Alcaraz A, Alekseev B, Iguchi T, Gomez-Veiga F, Croitoru R, Wu R, Kalac M, Tang Y, Stenzl A, Azad A. ARCHES: 5-year follow-up overall survival (OS) analysis of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC). Journal Of Clinical Oncology 2025, 43: 5005-5005. DOI: 10.1200/jco.2025.43.16_suppl.5005.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerAndrogen deprivation therapyOverall survivalOS analysisRadiographic progression-free survivalHormone-sensitive prostate cancerLong-term follow-upGlobal phase 3Low-volume patientsOpen-label enzalutamideProgression-free survivalEfficacy of enzalutamideMedian follow-upOpen-label extensionKaplan-Meier methodLong-term efficacyStandard-of-careClinically relevant subgroupsCox regression modelsFollow-up dataARCH trialDocetaxel useMedian OSAndrogen deprivationDisease volumeEP2.21 Periacetabular Osteotomies Lead to Improved Long-Term Patient-Reported Outcomes: A Systematic Review
Macleod J, Zhu J, Lee M, Surucu S, Gagne J, Patel S, Klug T, Park N, Norman M, Moran J, Jimenez A. EP2.21 Periacetabular Osteotomies Lead to Improved Long-Term Patient-Reported Outcomes: A Systematic Review. Journal Of Hip Preservation Surgery 2025, 12: i61-i62. PMCID: PMC11953899, DOI: 10.1093/jhps/hnaf011.197.Peer-Reviewed Original ResearchPatient-reported outcomesMean modified Harris Hip ScoreLong-term patient-reported outcomesTime of surgerySystematic reviewFollow-upPeriacetabular osteotomySecondary surgeryTreatment of hip dysplasiaPreoperative patient-reported outcome scoresOutcome scoresPreoperative patient-reported outcomesMerle d'Aubigne-Postel scoreRisk factorsLong-term follow-upPostoperative patient-reported outcomesRate of secondary surgerySecondary surgery ratePatient-reported outcome scoresPatient-reported scoresPreferred Reporting ItemsMidterm follow-upTerm follow-upFollow-up periodSignificant risk factorsVariations in Antithrombotic Prescriptions and Evaluation of Extended Clopidogrel Therapy After Lower Extremity Revascularization for Peripheral Artery Disease
Wells N, Alameddine D, Dhanda U, Tran L, Silva D, Slade M, Guzman R, Ochoa Chaar C. Variations in Antithrombotic Prescriptions and Evaluation of Extended Clopidogrel Therapy After Lower Extremity Revascularization for Peripheral Artery Disease. Journal Of Vascular Surgery 2025 PMID: 40122313, DOI: 10.1016/j.jvs.2025.03.183.Peer-Reviewed Original ResearchLower extremity revascularizationPeripheral arterial diseaseDuration of clopidogrel therapyClopidogrel therapyAntithrombotic prescriptionAntithrombotic combinationsAntithrombotic therapyExtremity revascularizationArtery diseasePatients treated with clopidogrelAssociated with improved survivalClinical characteristics of patientsMedical records of patientsLong-term follow-upChronic renal insufficiencyMACE-free survivalAssociated with bleedingElectronic medical records of patientsAdverse cardiac eventsKaplan-Meier curvesRecords of patientsTertiary care centerCongestive heart failureLong-term outcomesComparison of patientsAdvancements in minimally invasive interventional oncology procedures for painful sacral metastases under imaging guidance
Jiang W, Gan D, Johnson M, Latich I, Lee F. Advancements in minimally invasive interventional oncology procedures for painful sacral metastases under imaging guidance. EngMedicine 2025, 2: 100051. DOI: 10.1016/j.engmed.2024.100051.Peer-Reviewed Original ResearchPainful sacral metastasesIntra-operative image guidanceSacral metastasesImage guidancePreoperative baselineFollow-upPercutaneous interventionFunction scoresLong-term follow-upRisk of cement leakageO-arm navigationImprovement of painRetrospective cohort reviewImage guidance techniquesAverage follow-upInterventional oncology proceduresIntra-operative imaging techniquesO-armPercutaneous ablationSingle-institutionCohort reviewPrimary cancerClinical improvementMultiple myelomaCement leakageRisk of late sudden death after surgery for congenital heart disease.
Needleman J, Whitehill R, Claxton J, McCracken C, Zmora R, Vinocur J, Oster M, Kochilas L. Risk of late sudden death after surgery for congenital heart disease. Cardiology In The Young 2025, 35: 805-811. PMID: 40012309, DOI: 10.1017/s1047951125000277.Peer-Reviewed Original ResearchCongenital heart diseaseSudden cardiac deathSingle-ventricle physiologyCongenital heart surgerySudden cardiac death riskCardiac deathCardiac death riskHeart surgerySingle-ventricleHeart failurePediatric Cardiac Care Consortium RegistryRisk of late sudden deathLeft-to-right shunt lesionsLeft-to-right shuntCongenital heart disease typeMild congenital heart diseaseHeart diseaseLong-term follow-upDeath riskLate sudden deathGeneral populationCardiac death patientsSudden cardiac death patientsYears of ageMortality ratioEffectiveness of the 2023-to-2024 XBB.1.5 COVID-19 Vaccines Over Long-Term Follow-up : A Target Trial Emulation.
Ioannou G, Berry K, Rajeevan N, Li Y, Yan L, Huang Y, Lin H, Bui D, Hynes D, Rowneki M, Bohnert A, Boyko E, Iwashyna T, Maciejewski M, Smith V, Berkowitz T, O'Hare A, Viglianti E, Aslan M, Bajema K. Effectiveness of the 2023-to-2024 XBB.1.5 COVID-19 Vaccines Over Long-Term Follow-up : A Target Trial Emulation. Annals Of Internal Medicine 2025, 178: 348-359. PMID: 39903865, DOI: 10.7326/annals-24-01015.Peer-Reviewed Original ResearchConceptsU.S. Department of Veterans AffairsDepartment of Veterans AffairsMatched index dateVaccine effectivenessTarget trial emulationSARS-CoV-2-associated deathsRandomized controlled trialsCOVID-19 vaccineSARS-CoV-2-related outcomesSARS-CoV-2 testingVeterans AffairsResidual confoundingAbsence of randomized controlled trialsLong-term follow-upDocumented SARS-CoV-2 infectionTrial emulationUnvaccinated personsIndex datePositive resultsControlled trialsCOVID-19SARS-CoV-2 infectionIncomplete captureHospitalDocumented infection
2024
MDMA and MDMA-Assisted Therapy
Wolfgang A, Fonzo G, Gray J, Krystal J, Grzenda A, Widge A, Kraguljac N, McDonald W, Rodriguez C, Nemeroff C. MDMA and MDMA-Assisted Therapy. American Journal Of Psychiatry 2024, 182: 79-103. PMID: 39741438, DOI: 10.1176/appi.ajp.20230681.Peer-Reviewed Original ResearchConceptsMDMA-assisted therapyPosttraumatic stress disorderControlled clinical settingRecreational useMDMA administrationNeurobiological mechanismsStress disorderEgo functionsSelf-compassionMDMAEfficacious treatmentPreliminary evidenceHeightened trustTherapeutic settingNonclinical settingsDiagnostic criteriaFood and Drug AdministrationBreakthrough therapiesClinical settingNonmedical settingsConsiderable bodyPsychotherapyPsychedelicsLong-term follow-upDrug AdministrationLong-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma
Matei D, Enserro D, Randall M, Mutch D, Small W, DiSilvestro P, Spirtos N, O’Malley D, Cantuaria G, Michelin D, Waggoner S, Shahin M, Guntupalli S, Lara O, Ueland F, Warshal D, Bonebrake A, Tewari K, Tan A, Powell M, Walker J, Santin A, Kim J, Miller D. Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma. Journal Of Clinical Oncology 2024, 43: 1055-1060. PMID: 39700442, PMCID: PMC11908887, DOI: 10.1200/jco.24.01121.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalRandomized phase III trialOverall survivalC-RTFederation of Gynecology and Obstetrics (FIGOInternational Federation of Gynecology and Obstetrics (FIGOFollow-upIncreased recurrence-free survivalLocally advanced endometrial cancerLocally advanced endometrial carcinomaRate of local recurrenceLymph-vascular space invasionLong-term follow-upGross residual diseaseStratified hazard ratioProbability of OSAdvanced endometrial cancerMedian follow-upAdvanced endometrial carcinomaKaplan-Meier methodPhase III trialsBody mass indexMedian OSOS benefitPositive cytologyComparative Effectiveness of SBRT
Shen J, Sritharan D, Yu J, Aneja S. Comparative Effectiveness of SBRT. 2024, 455-467. DOI: 10.1007/978-3-031-67743-4_33.Peer-Reviewed Original ResearchStereotactic body radiation therapyEffect of stereotactic body radiation therapyAlternative to other treatment modalitiesStereotactic body radiation therapy treatmentLong-term follow-up of patientsFollow-up of patientsLong-term follow-upTreatment of brainOligometastatic diseaseRadiation therapyTreatment of cancerRetrospective seriesTreatment modalitiesRenal cancerCost-effectiveness studiesDatabase analysisCancerTreatmentProstateTherapyRenew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)
Komrokji R, Diez-Campelo M, Chee L, Cluzeau T, DeZern A, Fenaux P, Garcia-Manero G, Giagounidis A, Platzbecker U, Della Porta M, Santini V, Sekeres M, Zeidan A, Buckstein R, Ross M, Jiang Y, Bobba S, Hankin M, Materna C, Graham C, Thamake S, Rovaldi C, Grayson D, Salstrom J. Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS). Blood 2024, 144: 3228.1-3228.1. DOI: 10.1182/blood-2024-200797.Peer-Reviewed Original ResearchDurability of responseMyelodysplastic neoplasmsFollow-up periodTransfusion burdenProportion of participantsAdverse eventsTransfusion independenceIneffective hematopoiesisDouble-blindPlacebo-controlled phase 3 studyAchievement of transfusion independenceMultiple stages of hematopoiesisSafety follow-up periodDouble-blind treatment periodLong-term follow-up periodSeverity of adverse eventsLong-term follow-upErythroid maturation agentLow transfusion burdenSustained hematologic improvementTreatment of transfusion-dependent anemiaPlacebo-controlled studyTransfusion-dependent anemiaPhase 3 studyProgression to AML1622P A phase II study of the first-in-class oral innate immune activator BXCL701 with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC): Long-term follow-up
Aggarwal R, Tagawa S, Monk P, Zhu X, Jones R, Linch M, Costin D, de Bono J, Karsh L, Petrylak D, Borderies P, Deshpande R, O'Neill V, Zhang J. 1622P A phase II study of the first-in-class oral innate immune activator BXCL701 with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC): Long-term follow-up. Annals Of Oncology 2024, 35: s979. DOI: 10.1016/j.annonc.2024.08.1703.Peer-Reviewed Original Research616MO Long-term follow-up of single-agent divarasib in patients with KRAS G12C-positive solid tumors
Garralda E, Patel M, Kim T, Sacher A, Forster M, Santoro A, Desai J, Paz-Ares L, Gonzalez A, De Miguel M, Bowyer S, Dziadziuszko R, Kim S, Han S, Krebs M, Lorusso P, Cosman R, Chang J, Jun T, Miller W. 616MO Long-term follow-up of single-agent divarasib in patients with KRAS G12C-positive solid tumors. Annals Of Oncology 2024, 35: s494. DOI: 10.1016/j.annonc.2024.08.683.Peer-Reviewed Original ResearchLong-term follow-upSolid tumorsLong-term follow up of E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.
Burtness B, Flamand Y, Quon H, Weinstein G, Mehra R, Garcia J, Kim S, O'malley B, Ozer E, Koch W, Gross N, Bell R, Patel M, Lango M, Morris L, Smith R, Karakla D, Richmon J, Holsinger F, Ferris R. Long-term follow up of E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group. Journal Of Clinical Oncology 2024, 42: 6009-6009. DOI: 10.1200/jco.2024.42.16_suppl.6009.Peer-Reviewed Original ResearchProgression-free survivalIntermediate risk patientsExtranodal extensionOverall survivalPhase II trialRisk patientsSmoking historyPack-yearsPrimary siteLong-term follow-upFavorable pathologic characteristicsMature outcome dataPrescribed radiation doseECOG-ACRIN Cancer Research GroupPost-operative radiationIncreased recurrence riskKaplan-Meier methodLog-rank testPost-operative managementCancer Research GroupHPV+ OPCWeekly cisplatinMedian followN1 diseaseN1 patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply